CN106814063A - 一种稳定的血清铁检测试剂盒 - Google Patents
一种稳定的血清铁检测试剂盒 Download PDFInfo
- Publication number
- CN106814063A CN106814063A CN201510859182.2A CN201510859182A CN106814063A CN 106814063 A CN106814063 A CN 106814063A CN 201510859182 A CN201510859182 A CN 201510859182A CN 106814063 A CN106814063 A CN 106814063A
- Authority
- CN
- China
- Prior art keywords
- reagent
- iron
- serum levels
- buffer solutions
- detection kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 30
- 210000002966 serum Anatomy 0.000 title claims abstract description 30
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims description 121
- 229910052742 iron Inorganic materials 0.000 title claims description 61
- 230000006641 stabilisation Effects 0.000 title description 4
- 238000011105 stabilization Methods 0.000 title description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000007983 Tris buffer Substances 0.000 claims abstract description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims abstract description 11
- 239000004094 surface-active agent Substances 0.000 claims abstract description 7
- 239000007853 buffer solution Substances 0.000 claims abstract description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 16
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 15
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical class [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000002211 L-ascorbic acid Substances 0.000 claims description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 2
- 235000000396 iron Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000005293 ferrimagnetic effect Effects 0.000 abstract description 3
- QMPKHBWKQLDRGR-UHFFFAOYSA-N iron;piperazine Chemical compound [Fe].C1CNCCN1 QMPKHBWKQLDRGR-UHFFFAOYSA-N 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 7
- 102000008857 Ferritin Human genes 0.000 description 6
- 108050000784 Ferritin Proteins 0.000 description 6
- 238000008416 Ferritin Methods 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 208000007502 anemia Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- -1 oxygen radical Chemical class 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 108010017480 Hemosiderin Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910001448 ferrous ion Inorganic materials 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- 102000002070 Transferrins Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 238000000705 flame atomic absorption spectrometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 108010045676 holotransferrin Proteins 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
Landscapes
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510859182.2A CN106814063B (zh) | 2015-12-01 | 2015-12-01 | 一种稳定的血清铁检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510859182.2A CN106814063B (zh) | 2015-12-01 | 2015-12-01 | 一种稳定的血清铁检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106814063A true CN106814063A (zh) | 2017-06-09 |
CN106814063B CN106814063B (zh) | 2019-03-12 |
Family
ID=59156374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510859182.2A Active CN106814063B (zh) | 2015-12-01 | 2015-12-01 | 一种稳定的血清铁检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106814063B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109613280A (zh) * | 2018-12-29 | 2019-04-12 | 中拓生物有限公司 | 一种血清铁测定试剂盒及其制备方法和应用 |
CN110865075A (zh) * | 2019-12-31 | 2020-03-06 | 南通大学 | 一种常规的尿铁检测试剂盒及其检测方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101629960A (zh) * | 2008-07-18 | 2010-01-20 | 中生北控生物科技股份有限公司 | 铁测定试剂组合、试剂盒及其应用 |
CN104483494A (zh) * | 2014-12-22 | 2015-04-01 | 宁波美康生物科技股份有限公司 | 一种血清不饱和铁结合力检测试剂盒 |
-
2015
- 2015-12-01 CN CN201510859182.2A patent/CN106814063B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101629960A (zh) * | 2008-07-18 | 2010-01-20 | 中生北控生物科技股份有限公司 | 铁测定试剂组合、试剂盒及其应用 |
CN104483494A (zh) * | 2014-12-22 | 2015-04-01 | 宁波美康生物科技股份有限公司 | 一种血清不饱和铁结合力检测试剂盒 |
Non-Patent Citations (3)
Title |
---|
曹建明等: "《新的高灵敏分光光度法在血清铁测定中的应用》", 《中华检验医学杂志》 * |
王丹等: "一种灵敏的血清铁比色法测定", 《临床检验杂志》 * |
连国军等: "以 Nitro- PAPS 为显色剂计算法测定血清总铁结合力", 《广东微量元素科学》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109613280A (zh) * | 2018-12-29 | 2019-04-12 | 中拓生物有限公司 | 一种血清铁测定试剂盒及其制备方法和应用 |
CN109613280B (zh) * | 2018-12-29 | 2022-01-28 | 中拓生物有限公司 | 一种血清铁测定试剂盒及其制备方法和应用 |
CN110865075A (zh) * | 2019-12-31 | 2020-03-06 | 南通大学 | 一种常规的尿铁检测试剂盒及其检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106814063B (zh) | 2019-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ōyanagui | Reevaluation of assay methods and establishment of kit for superoxide dismutase activity | |
Ellis et al. | Nitrite and nitrate analyses: a clinical biochemistry perspective | |
Vázquez-Fresno et al. | Clinical phenotype clustering in cardiovascular risk patients for the identification of responsive metabotypes after red wine polyphenol intake | |
Kelm et al. | Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: evidence for biochemical assessment of the endothelial L-arginine–NO pathway | |
ES2804205T3 (es) | Método de análisis para componente de muestra biológica diluida | |
Oakes et al. | Acute inflammatory response does not affect erythrocyte concentrations of copper, zinc and selenium | |
CN105264384B (zh) | 参比材料中不稳定分析物的稳定化 | |
Singh et al. | Mode of binding of the tuberculosis prodrug isoniazid to heme peroxidases: binding studies and crystal structure of bovine lactoperoxidase with isoniazid at 2.7 Å resolution | |
CN102621332B (zh) | 基于胶乳粒子包被视黄醇结合蛋白检测试剂盒 | |
CN103760357B (zh) | 一种缺血修饰白蛋白检测试剂盒 | |
Hotz et al. | Natural iron isotopic composition of blood is an indicator of dietary iron absorption efficiency in humans | |
Farina et al. | Effects of aluminum sulfate on erythropoiesis in rats | |
CN104120165B (zh) | 一种稳定性强的同型半胱氨酸检测试剂盒 | |
Dent et al. | Measuring magnesium–Physiological, clinical and analytical perspectives | |
Amin et al. | Homocysteine as a predictive biomarker in early diagnosis of renal failure susceptibility and prognostic diagnosis for end stages renal disease | |
Di Bernardo et al. | Intracellular anion fluorescence assay for sodium/iodide symporter substrates | |
WO2018117129A1 (ja) | 尿検査装置および尿検査方法 | |
CN106814063A (zh) | 一种稳定的血清铁检测试剂盒 | |
Li et al. | Associations between rice consumption, arsenic metabolism, and insulin resistance in adults without diabetes | |
Dill et al. | Diet-related urine collections: assistance in categorization of hyperoxaluria | |
CN109738623A (zh) | 一种血清α1-酸性糖蛋白测定试剂盒 | |
Malczewska et al. | The effects of physical exercise on the concentrations of ferritin and transferrin receptor in plasma of male judoists | |
CN106814191A (zh) | 一种视黄醇结合蛋白免疫比浊法检测试剂盒 | |
Mishra et al. | Antioxidant status of children with acute renal failure | |
Reddy et al. | Gender differences in alcohol-induced oxidative stress and altered membrane properties in erythrocytes of rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Stable Serum Iron Detection Kit Effective date of registration: 20230628 Granted publication date: 20190312 Pledgee: Bank of Communications Ltd. Shandong branch Pledgor: BIOBASE BIODUSTRY (SHANDONG) Co.,Ltd. Registration number: Y2023980045843 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20190312 Pledgee: Bank of Communications Ltd. Shandong branch Pledgor: BIOBASE BIODUSTRY (SHANDONG) Co.,Ltd. Registration number: Y2023980045843 |